Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Webcasts|September 21, 2022

Advantages of a One-Stop Shop for Freeze/Thaw And Cold-Chain Process Development

Author(s)Entegris

Wed, Sep 21, 2022 2:00 PM EDT This webinar will review the key considerations and gaps in evaluating freeze/thaw solutions, examine the elements of a dedicated technology center to bridging these gaps and development risks, and explore successful case studies of a technology center optimizing processes and speed-to-market.

Register Free: https://www.biopharminternational.com/bp/one-stop

Event Overview:

The current market for freeze/thaw equipment is limited to a few core suppliers and solutions. As more biopharmaceutical companies begin identifying a need for these technologies for their biotherapeutics, many may choose to incorporate freeze/thaw equipment into their processes without assessing and optimizing the system solution through testing and validation with their product. This can lead to product mismatch, suboptimal performance, and increased risk. To mitigate the potential issues that can arise from inadequate testing, a Technology Center was built to provide a world-class laboratory dedicated to affording customers access to testing for the equipment and containers that will form the foundation of their freeze/thaw process. This webinar will:

  • Review the key considerations and gaps in evaluating freeze/thaw solutions
  • Examine the elements of a dedicated technology center to bridging these gaps and development risks
  • Explore successful case studies of a technology center optimizing processes and speed-to-market.

Key Learning Objectives:

  • Understand the challenges with developing and optimizing inherently inefficient freeze/thaw workflows
  • Understand the tools and support needed to properly evaluate cold chain solutions for a scaled-up multi-site process
  • Learn the importance of having market access to leading technologies, the capability to develop bespoke solutions, and building the foundation for a robust platform to adopt an optimal process.

Who Should Attend:

  • Manufacturing science and technology (MS&T) engineers/scientists
  • Process development engineers/scientists
  • Associate/senior directors of process sciences and manufacturing

Muhammad Siddiqui
Cold Chain Applications Engineer
Entegris

Donnie Beers
Gene Therapy Applications Leader
Entegris

Register Free: https://www.biopharminternational.com/bp/one-stop


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.